1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEIbiglustat L-Malic acidCat. No.: HY-16743ACAS No.: 1629063-78-0Synonyms: Venglustat (L-Malic acid); SAR402671 (L-Malic acid);GZ402671 (L-Malic acid)分式: CHFNOS分量: 523.57作靶點: Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn s

2、olvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 102 mg/mL (194.82 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.9100 mL 9.5498 mL 19.0996 mL5 mM 0.3820 mL 1.9100 mL 3.8199 mL10 mM 0.1910 mL 0.9550 mL 1.9100 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式

3、和期限。BIOLOGICAL ACTIVITY物活性 Ibiglustat L-Malic acid (Venglustat L-Malic acid)種潛在的帕森病、法布病和謝病的治療藥物，是選擇性的、葡糖神經酰胺合成酶 (GCS) 的變構抑制劑，能通過腦屏障 1 2 3。IC50 & Target Glucosylceramide synthase 1.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體外研究 Ibiglustat (SAR402671) (1 M, 15 days) treated FD cells are close t

4、o the physiological level in untreated WTcells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve toameliorate the abundant levels of this sphingolipid in FD cardiomyocytes 4.REFERENCES1. WO 2015089067 A1.2. Iva Stojkovska, et al. Molecular mechanisms

5、 of -synuclein and GBA1 in Parkinsons disease. Cell Tissue Res. 2017.3. Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 16871700.4. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014Nov;37(6):1013-22.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;